Pharmalink elects three to board
pharmafile | July 4, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Ann-Tove Kongsnes, Hilde Furberg, Olav Hellebø, Pharmalink, ab
Swedish speciality pharma firm Pharmalink AB has appointed Ann-Tove Kongsnes, Hilde Furberg and Olav Hellebø to its board of directors.
Kongsnes (pictured) was previously an investment manager at ProVenture Management. Prior to that she was a business development manager at Leiv Eiriksson Nyskaping; a director of marketing and operations at NSEC; and a marketing manager at the Norwegian Seafood Export Council.
Furberg has 30 years of experience in the pharma industry. She is currently a senior VP for rare diseases (EMEA) at Sanofi’s Genzyme, which she joined in 2002. Prior to this role Furberg spent 15 years at Baxter in various business positions of increasing seniority, before which she was involved in the start-up of Pharmalink.
Hellebø is the chairman and co-founder of Palma Biotech in Spain, and prior to that was chief executive of Clavis Pharma following a senior VP position at UCB Pharma and president of Immunology Operations.
Hellebø was chief operating officer of Novartis UK from 2003 to 2004, and prior to that held a series of senior international roles at Schering Plough, the last as head of its oncology biotech division in the US.
Anders Wiklund, Pharmalink’s chairman, says: “We are very pleased to welcome Ann-Tove, Hilde, and Olav to the Pharmalink board. Between them, they have a wealth of experience in the global pharma industry, in the development and commercialisation of innovative new therapies, as well as more broadly in corporate development. We would also like to thank Elisabeth Lindner, who has stepped down from the board.”
